MOTS-c vs SS-31
Written by the Pure Peptides editorial team
Reviewed by Dr. Martina Rossi, PhD
Scientific Contributor and Reviewer · Reviewed
Published · Updated · 9 references
MOTS-c and SS-31 are different molecules: MOTS-c is a 16-residue peptide encoded within a ribosomal RNA gene, and SS-31 is a four-residue peptide containing a D-arginine.
Structure at a glance
MOTS-c · 16 residues
SS-31 · 4 residues
NH2: C-terminal amide. A raised D marks a D-amino acid. Dmt: dimethyltyrosine. Codes are three-letter amino acid codes.
Drawn from the product database. Each measure's bars share one scale.
| Property | MOTS-c | SS-31 |
|---|---|---|
| What it is | A 16-residue peptide encoded by a short open reading frame within the mitochondrial 12S rRNA gene.[1] Ends in a free C-terminal acid. | A tetrapeptide, also named elamipretide.[2][3] Four residues, with a D-arginine and a C-terminal amide. |
| How they relate | Different molecules. MOTS-c is encoded by a short open reading frame within the mitochondrial 12S rRNA gene.[1] SS-31 is a synthetic tetrapeptide.[2][3] | |
| CAS number | 1627580-64-6 | 736992-21-5 |
| Molecular formula | C101H152N28O22S2 | C32H49N9O5 |
| Molecular weight | 2,174.62 g/mol | 639.80 g/mol |
| Sequence | Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg | D-Arg-dimethylTyr-Lys-Phe-NH2 |
| Evidence base | Animal and cell studies. No completed controlled study testing MOTS-c in people has published results. Human studies in the literature reviewed for it measured the body's own MOTS-c. | Randomized human trials. One, in an indication other than the approved one, was negative on its primary endpoint and every prespecified secondary.[4] The developer sponsored essentially the entire clinical program.[5] |
| Regulatory status | MOTS-c is not approved for human therapeutic use, and Drugs@FDA holds no approved application for it.[6] | Elamipretide hydrochloride holds an accelerated US approval, granted in September 2025, for one therapeutic indication.[7][8] |
| Compared head-to-head? | No direct comparison found in PubMed (searched October 2026).[9] | |
| Handling difference | MOTS-c has three oxidation-prone residues: two methionines and a tryptophan. SS-31 contains no sulfur; its D-arginine could epimerize, a change that leaves formula and mass unchanged. | |
How MOTS-c and SS-31 differ
MOTS-c and SS-31 are different molecules. MOTS-c is a 16-residue peptide encoded by a short open reading frame within the mitochondrial 12S rRNA (ribosomal RNA) gene.[1] Its chain ends in a free C-terminal acid. SS-31 is a synthetic tetrapeptide, and elamipretide is another name for the same molecule.[2][3] Its four residues include a D-arginine, and its chain ends in a C-terminal amide.
No completed controlled study testing MOTS-c in people has published results. In the literature reviewed for MOTS-c, the human studies measured the body's own MOTS-c. The findings of the 2015 paper that first described MOTS-c are animal and cell findings, and none of them has been shown in humans.[1] The literature reviewed for MOTS-c reports no human safety data. SS-31 has been tested in randomized human trials. One, in an indication other than the approved one, was negative on its primary endpoint and on every prespecified secondary.[4] The compound's developer sponsored essentially the entire clinical program in the literature reviewed for SS-31.[5]
Elamipretide hydrochloride holds an accelerated US approval, granted in September 2025, for one therapeutic indication.[7][8] That approval does not extend to research-grade material, to any other indication, or to any other compound. Elamipretide hydrochloride is the active ingredient of a prescription medicine sold under another name. The material supplied here is a research-grade preparation, is not that medicine, and holds no marketing authorization. That medicine's label carries a warning about hypersensitivity reactions.[5] MOTS-c is not approved for human therapeutic use, and Drugs@FDA holds no approved application for it.[6]
MOTS-c carries two methionines and a tryptophan, three residues that can each take up oxygen when exposed to air, light or trace metals. A glutamine gives it a second, slower route, deamidation in solution. SS-31 contains no sulfur, so it has no methionine to oxidize, and it has no residue open to deamidation. SS-31 contains a D-arginine, and a peptide epimerized at that residue, during synthesis or later, keeps an identical formula and mass, so mass spectrometry cannot detect it. Neither can form a disulfide, and both carry a substantial net positive charge. Each is usually supplied as a salt after solid-phase synthesis and purification, and in both the counter-ion makes up a large share of the material.
Have MOTS-c and SS-31 been compared directly?
No direct comparison of MOTS-c with SS-31 was found in a PubMed search run in October 2026.[9] That search covers PubMed only.
Read more on each compound
MOTS-c
Frequently Asked Questions
Is MOTS-c the same as SS-31?+−
MOTS-c and SS-31 are different molecules: MOTS-c is a 16-residue peptide encoded within a ribosomal RNA gene, and SS-31 is a four-residue peptide containing a D-arginine. Elamipretide is another name for SS-31.
Is MOTS-c or SS-31 approved?+−
MOTS-c is not approved for human therapeutic use; elamipretide hydrochloride, a salt of the SS-31 molecule, is the active ingredient of a prescription medicine sold under another name. The material supplied here is a research-grade preparation, is not that medicine, and holds no marketing authorization.
References
- 2NCBI PubChem. Compound records for the free base and the trihydrochloride. Retrieved 28 August 2026.
- 3Tung C. International Journal of Molecular Sciences, 2025. PMID 39940712. DOI: 10.3390/ijms26030944.
- 5US Food and Drug Administration. Approved prescribing information for elamipretide; approval date 20250919, label version 20251210. Retrieved via field-qualified openFDA queries.
- 6US Food and Drug Administration. openFDA drug/label and drug/drugsfda endpoints, snapshot last updated 2026-08-26. Field-qualified substance-name query returned no record for MOTS-c.
- 8US Food and Drug Administration, Drugs@FDA. Approval record whose active ingredient is elamipretide hydrochloride. Retrieved via api.fda.gov/drug/drugsfda.json on products.active_ingredients.name "ELAMIPRETIDE HYDROCHLORIDE", 3 October 2026.
- 9
PubMed search, 3 October 2026 (records to 2 October 2026)
1 record; none was a direct comparison of the two compounds.
Exact query (NCBI E-utilities): ("MOTS-c"[tiab] OR "MOTSc"[tiab] OR "MOTS c"[tiab]) AND ("SS-31"[tiab] OR "SS31"[tiab] OR "SS 31"[tiab] OR "elamipretide"[tiab]) AND ("1800/01/01"[edat] : "2026/10/02"[edat])
View this search on PubMed

Reviewed for scientific accuracy
Dr. Martina Rossi, PhD
PhD, Université Grenoble Alpes · Scientific Contributor and Reviewer
Dr. Rossi's doctoral research at Université Grenoble Alpes examined the vascular functions of bone morphogenetic proteins. Her peer-reviewed work spans cell and molecular biology, vascular biology, and gene therapy, in journals including Cardiovascular Research, Scientific Reports, and Brain Sciences. She reviews Pure Peptides' product, reference, and research pages for scientific accuracy against the sources they cite.
Related comparisons
MOTS-c vs NAD+
MOTS-c and NAD+ are different molecules: a 16-residue peptide encoded in a ribosomal RNA gene and a dinucleotide, not a peptide.
Read ComparisonMOTS-c vs Tesamorelin
MOTS-c and Tesamorelin are different molecules: a 16-residue peptide encoded in a ribosomal RNA gene and a 44-residue analog of human GHRH.
Read ComparisonAOD-9604 vs HGH Fragment 176-191
AOD-9604 and HGH Fragment 176-191 are 16-residue peptides from the C-terminal end of human growth hormone that differ at one position.
Read Comparison

